Skip to main content
MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. logo

MABWELL (SHANGHAI) BIOSCIENCE CO., LTD. — Investor Relations & Filings

Ticker · 688062 ISIN · CNE100005RD2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 541 across all filing types
Latest filing 2024-04-08 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688062

About MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.

https://www.mabwell.com/en/

Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of therapeutic antibodies and innovative biologics. The company maintains an integrated R&D and manufacturing platform covering the full drug lifecycle, from target discovery and preclinical research to clinical development and commercial production. Its therapeutic pipeline addresses critical needs in oncology, autoimmune diseases, metabolic disorders, ophthalmology, and infectious diseases. Mabwell leverages proprietary technology platforms, including antibody-drug conjugates (ADCs), bispecific antibodies, and high-throughput screening, to develop a diverse portfolio of novel drug candidates and biosimilars. The organization is committed to delivering high-quality, accessible therapeutic solutions through its end-to-end biotechnological capabilities.

Recent filings

Filing Released Lang Actions
迈威生物董事会关于独立董事独立性自查情况的专项报告
Board/Management Information Classification · 95% confidence The document is a special report on the independence of the company's independent directors, including a self-assessment and the board's evaluation of their independence. It references compliance with regulatory rules on independent directors and governance standards. The content focuses on governance and board-related information rather than financial results, audit, or shareholder voting. It is not an announcement of a meeting or voting results, nor a financial report or earnings release. The document fits best under Board/Management Information (MANG) as it relates to board members' status and independence.
2024-04-08 Chinese
迈威生物2023年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2023年度董事会审计委员会履职情况报告" which translates to "2023 Annual Board Audit Committee Performance Report." It details the audit committee's activities, meetings, supervision of external audit work, review of financial reports, internal control oversight, and internal audit guidance for the year 2023. The content focuses on the audit committee's role and their review and oversight functions rather than presenting the full annual financial statements or the full audit report itself. The document length is 3274 characters, which is relatively short and consistent with a committee report rather than a full annual report or standalone audit report. It is not a certification or a brief announcement but a detailed committee report on their duties and findings. This fits best under the category of Audit Report / Information (AR), which includes reports on audit committee activities and audit-related oversight, excluding full annual reports. Therefore, the classification is AR with high confidence.
2024-04-08 Chinese
迈威生物非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation report on non-operating fund occupation and other related party fund transactions for the fiscal year 2023. It includes references to audited financial statements for the year ending December 31, 2023, and an audit report issued by a certified public accountant. The content focuses on financial data related to fund usage and related party transactions, with tables of financial figures and audit confirmations. It is not a full annual report but a standalone audit-related disclosure concerning specific financial matters. The document is substantive and contains detailed financial data, not merely an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR).
2024-04-08 Chinese
海通证券股份有限公司关于迈威（上海）生物科技股份有限公司为全资子公司提供担保额度预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the anticipated guarantee amount for its wholly-owned subsidiaries. It includes extensive financial data, company background, board and independent director opinions, and compliance with regulatory rules. The document is not an announcement of a report publication but contains substantive financial and operational information related to the guarantee. It is not a general regulatory filing, earnings release, or capital update but a formal audit or verification opinion related to financial guarantees and risk assessment. The presence of audit opinions, financial data, and regulatory compliance points to an Audit Report / Information filing rather than a general announcement or other categories.
2024-04-08 Chinese
迈威生物2023年度独立董事述职报告（许青）
Management Reports Classification · 95% confidence The document is titled as the "2023年度独立董事述职报告(许青)" which translates to the "2023 Annual Independent Director's Work Report (Xu Qing)". It details the independent director's duties, attendance, committee participation, oversight activities, and evaluations for the year 2023. The content focuses on the director's report on their role and activities rather than financial statements or audit results. It is a detailed management-related report about the director's performance and governance oversight. This fits best under the category of Management Reports (MDA), which covers management's detailed explanation of business trends, governance, and outlook. It is not an Annual Report (10-K), Audit Report (AR), or Governance Information (CGR) since it is a personal director's report. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive content and is not merely an announcement. Therefore, the classification is MDA with high confidence.
2024-04-08 Chinese
迈威生物2023年度营业收入扣除情况专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度营业收入扣除情况专项说明" which translates to "2023 Annual Special Explanation on Deduction of Operating Income". It includes detailed financial data such as consolidated balance sheets, profit and loss statements, shareholders' equity changes, and cash flow statements for the year ending December 31, 2023. The document is prepared by an accounting firm (Ernst & Young Hua Ming) and includes an audit opinion dated April 8, 2024. The content focuses on a specific financial audit and explanation related to revenue deductions as per regulatory guidelines from the Shanghai Stock Exchange. It is not a full annual report but a standalone audit-related report focusing on a particular financial aspect. The document length is substantial (15,000 characters), and it contains actual financial data and audit conclusions. Therefore, it fits best under the category of Audit Report / Information (AR).
2024-04-08 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.